Bildkälla: Stockfoto

Biovica expands clinical support - Redeye

Expanding clinical evidence and market opportunities is the key to Biovica’s future opportunities once approved. This year’s US SABCS conference (7-10 December) will feature three studies where Biovica’s DiviTum is featured monitoring treatment in women with metastatic breast cancer (mBC).

Expanding clinical evidence and market opportunities is the key to Biovica’s future opportunities once approved. This year’s US SABCS conference (7-10 December) will feature three studies where Biovica’s DiviTum is featured monitoring treatment in women with metastatic breast cancer (mBC).
Börsvärldens nyhetsbrev
ANNONSER